MEG3 and central nervous system cancer: Analysis of MEG3 expression in glioma patients showed that low expression of MEG3 was associated with poor overall survival rates, advanced WHO grade, low Karnofsky performance score (KPS), isocitrate dehydrogenase (IDH) wild-type, and tumor recurrence [60,125].